BEIJING, Dec. 27, 2021 /PRNewswire/ — La Chine & l‘espace arabo-africain, the French version of the book titled “China and Arabic & African Regions Pursuing the Belt and Road Initiative” authored by the Economist Fathallah Oualalou, Former Minister of Economy and Finance of Morocco and Senior Fellow at the Policy Center for the New South, came out in France. The author holds that the New Silk Road, or rather the Belt and Road definitely represents a way to redefine our world and the world balance and enables us to get a deeper understanding about how the African and Arabic countries relate to the Belt and Road.
On December 16, 2021, the new book launch and the seminar themed on China-Arabic and China-African Cooperation Opportunities and Challenges were held online and offline, organized by Les Éditions de la Route de la Soie and China National Publications Import and Export (Group) Co., Ltd. (CNPIEC). Fathallah Oualalou, Former Minister of Economy and Finance of Morocco, Senior Fellow at the Policy Center for the New South, Economist; Mohammed Khalil, President of Morocco-China Friendship Association; David Monyae, Director of the Center for Africa-China Studies at the University of Johannesburg, South Africa; Khaled Elhaj Ahmed, Sinologist and Dean of the Department of Oriental Languages, the Higher Institute of Languages, Carthage University, Tunisia; Sonia Bressler, Chief Editor of Silk Road Publishing House (Les Éditions de la Route de la Soie); Mohamad Elkhatib, President of Digital Future Ltd.; Xue Qingguo, Professor of the School of Arabic Studies, Beijing Foreign Studies University (BFSU), Director of the BFSU Zayed Center for Arabic Language and Islamic Studies, and Vice President of the Chinese Society for the Study of Arabic Literature; Liu Xinlu, Dean of the School of Arabic Studies, BFSU; and Zhang Yongpeng, Researcher of the Institute for West-Asian and African of the Chinese Academy of Social Sciences among other Chinese and foreign scholars and experts discussed the contents of the book.
The speakers at the meeting agreed that it is a significant book expounding the Belt and Road Initiative and its impact upon the African continent and the Middle East, responding to the challenges related to health, poverty, environment, technological revolution and world reshaping. Overseas scholars indicate the new world landscape is taking shape under new circumstances and the Belt and Road Initiative has brought many hopes in this process. China is like a locomotive of the world’s development; it is a great driving force. It should better participate in the construction of the world landscape to usher in a more peaceful, balanced, mutually beneficial, friendly and inclusive future.
The French version of the book was first published. In the future, the Chinese version and Arabic version will also be published by Guangming Daily Press of China and Digital Future Ltd. respectively.
VLN® Is World’s First and Only Combustible Cigarette to Receive FDA MRTP Designation
FDA Adds Evidence-Based, Headline Claim “Helps You Smoke Less” to Company’s Requested Claims
VLN® 95% Reduced Nicotine Content Cigarettes to Launch in the U.S. Within 90 Days
VLN® to Launch Outside the U.S. in First Quarter 2022
BUFFALO, N.Y., Dec. 23, 2021 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, announced today that the U.S. Food and Drug Administration (FDA) has authorized the marketing of the Company’s VLN® King and VLN® Menthol King reduced nicotine content cigarettes as modified risk tobacco products (MRTPs). In doing so, the Agency found that VLN® – which smokes, tastes, and smells like a conventional cigarette but contains 95% less nicotine than conventional, highly addictive cigarettes – “help reduce exposure to, and consumption of, nicotine for smokers who use them.”
“Today’s decision to authorize VLN®’s MRTP application places the FDA and 22nd Century together at the vanguard of transforming the tobacco industry. With 60% of adult smokers in our U.S. market research telling us they are likely to try VLN®, this is a complete game-changer for 22nd Century, the tobacco industry, public health, and adult smokers looking to change their relationship with nicotine – the addictive chemical found in all tobacco products. This is the first, and most likely will be the only, combustible cigarette to ever carry the FDA’s MRTP designation. The FDA’s decision to require the additional headline claim ‘Helps You Smoke Less’ alongside our requested headline claim of ‘95% Less Nicotine’ gives adult smokers a crystal-clear reason to replace their conventional and highly addictive cigarettes with VLN®,” said James A. Mish, chief executive officer at 22nd Century Group.
“Our mission is to find ways to stop tobacco-related disease and death. We know that three out of four adult smokers want to quit and the data on these products show they can help addicted adult smokers transition away from highly addictive combusted cigarettes,” said Mitch Zeller, J.D., director of the FDA’s Center for Tobacco Products. “Having options like these products authorized today, which contain less nicotine and are reasonably likely to reduce nicotine dependence, may help adult smokers. If adult smokers were less addicted to combusted cigarettes, they would likely smoke less and may be exposed to fewer harmful chemicals that cause tobacco-related disease and death.”
“Having secured this FDA marketing order, we are fully prepared to launch VLN® with select retail and marketing partners in our pilot markets in the U.S. within the next 90 days and in the first of several global markets by the end of the first quarter of 2022. We are also in discussions with additional retail trade, marketing, and strategic partners to scale VLN® sales in the U.S. and internationally, including through potential licensing of our technology to facilitate the broader industry transition to RNC products. We will provide additional details on strategic partners and the rollout of VLN® in the coming months,” said Mish.
The FDA authorized the marketing of VLN® with the following MRTP claims:
“Helps you smoke less.”
“95% less nicotine.”
“Helps reduce your nicotine consumption.”
“…Greatly reduces your nicotine consumption.”
The FDA’s decision to authorize the Company’s MRTP claims and to require the additional claim of “Helps You Smoke Less” on every VLN® pack and in every VLN® advertisement where any of the other authorized claims are also used was based on an extensive body of science consisting of dozens of independent scientific and clinical studies using 22nd Century’s reduced nicotine content (RNC) tobacco cigarettes. These studies, which were funded largely by the FDA, the National Institutes of Health (NIH), and other U.S. federal government agencies, as well as studies funded by 22nd Century, show that smokers who use RNC cigarettes – even those with no intention of quitting at the beginning of the studies – reduce their nicotine exposure and dependence, smoke fewer cigarettes per day, increase their number of smoke-free days, and double their quit attempts – all with minimal or no evidence of nicotine withdrawal symptoms or compensatory smoking.
In its announcement of its decision today, FDA explained, “The data also showed it is reasonably likely that using these products reduces nicotine dependence, which is anticipated to lead to long-term reductions in exposure to the smoking-related toxicants associated with morbidity and mortality by reducing smoking. Published studies have shown that significantly reducing the number of cigarettes smoked per day is associated with lower risk of lung cancer and death, with greater reductions in cigarettes per day resulting in less risk. Additionally, as required for authorization, the FDA found that the applications supported consumer understanding of the claims that VLN® cigarettes contain much lower levels of nicotine than other cigarettes.”
VLN® is also the first and only combustible cigarette to come to market that complies with the FDA’s proposed nicotine cap for conventional cigarettes in its Comprehensive Plan for Tobacco and Nicotine Regulation as well as New Zealand’s recently proposed reduced nicotine content mandate.
“We believe today’s announcement by the FDA is a clear indication that the FDA is moving forward with its Plan to address the incredible harms caused by smoking. This plan includes the authorization of less toxic tobacco products such as e-cigarettes and other non-combustible products along with a nicotine cap of 0.5 mg of nicotine per gram of tobacco in combustible tobacco products. This level of nicotine content, which the FDA has described as being ’minimally or non-addictive,’ has already been achieved by 22nd Century in its VLN® products,” said Mish.
The FDA reiterated in its announcement today that it is “committed to moving forward with the rulemaking process to ban menthol as a characterizing flavor in cigarettes and all characterizing flavors in cigars and remains on track to issue proposed rules in the spring of 2022” and that both VLN® King and VLN® Menthol King cigarettes “could help addicted cigarette smokers reduce their nicotine consumption and the number of cigarettes they smoke per day.”
“As the FDA also looks to ban menthol in highly addictive cigarettes, we fully expect the FDA will allow our VLN® Menthol cigarettes, which offer little appeal for youth and former smokers because of their reduced nicotine content, to be allowed by the FDA to remain on the market to provide an off-ramp for adult smokers of menthol cigarettes,” added Mish.
The FDA’s decision further builds on research projecting that an industry product standard to lower nicotine content in cigarettes to minimally or non-addictive levels would significantly change the trajectory of cigarette addiction, which is the leading cause of preventable disease and death in the U.S. Approximately five million adult smokers would quit within just one year of implementation, more than 33 million people would avoid becoming regular smokers, and more than eight million premature deaths from tobacco could be avoided. With almost half a million Americans dying from smoking and more than $300 billion spent per year on smoking-related diseases, there is a clear and urgent need for substantial change in the tobacco industry.
22nd Century is ready to supply the market with RNC tobacco and finished products such as VLN® to enable both 22nd Century and other manufacturers to comply with the proposed nicotine caps in the U.S., New Zealand and other countries as they embrace this innovative and highly effective approach to tobacco harm reduction first proposed by the WHO in 2015. 22nd Century’s plant-based technology and products are superior to costly extraction and similar de-nicotinization technologies because those technologies typically use chemicals that strip out not just nicotine but also flavor and aroma compounds, resulting in a product that has been found unacceptable to smokers because it delivers no smoking satisfaction. In contrast, 22nd Century’s reduced nicotine tobacco naturally grows with very low levels of nicotine resulting in products that smoke, taste and smell like conventional cigarettes but contain 95% less nicotine than conventional, highly addictive cigarettes. This is critical to creating an acceptable solution and “off-ramp” for current smokers looking to change their relationship with nicotine.
22nd Century remains committed to licensing its technology and products to every manufacturer to enable industry wide compliance with the proposed nicotine caps.
About 22nd Century Group, Inc.
22nd Century Group, Inc. (Nasdaq: XXII) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA’s Comprehensive Plan to address the widespread death and disease caused by smoking. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.
Cautionary Note Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 11, 2021. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.
Investor Relations & Media Contact:
Mei Kuo
Director, Communications & Investor Relations
22nd Century Group, Inc.
(716) 300-1221 [email protected]
HVDC Light® will connect low-carbon power from the mainland grid to ADNOC’s production operations as a strategic project to enable a sustainable, flexible and secure power supply.
Zurich, Switzerland, Dec. 22, 2021 (GLOBE NEWSWIRE) — Hitachi Energy today announced it has won a major order from Samsung C&T Corporation, one of the world’s largest engineering and construction companies, to connect ADNOC’s offshore operations to the onshore power grid in the United Arab Emirates owned and operated by Abu Dhabi National Energy Company PJSC (TAQA).
Hitachi Energy’s HVDC Light® technology and MACHTM digital control platform1 will enable the transfer of cleaner and more efficient power from the mainland to power ADNOC’s offshore production operations, enabling a carbon footprint reduction of ADNOC’s offshore operations by more than thirty percent.
This innovative solution reinforces Hitachi Energy’s commitment to helping customers and countries to transition towards a carbon-neutral future and help enable the ‘2050 Net-Zero Initiative’ of the UAE.
With a capacity of 3,200 megawatts (MW), the two HVDC links will be by far the most powerful power-from-shore solution in the Middle East and North America (MENA) region to date. It is also the first HVDC power-from-shore solution outside Norwegian waters. This innovative solution reflects how Hitachi Energy continues to pioneer technology to address the growing interest from national and independent oil and gas companies to power their offshore production facilities with carbon-free energy from onshore power grids.
“We are proud to be enabling Abu Dhabi and ADNOC to make significant progress on their pathway toward achieving the United Arab Emirates’ ambition to be carbon-neutral by 2050,” said Claudio Facchin, CEO of Hitachi Energy. He continued, “At Hitachi Energy we are championing the urgency of the clean energy transition, and this major order is further evidence that we are a ‘go to’ partner for developing and deploying technologies and solutions that are advancing the world’s energy system to be more sustainable, flexible and secure.”
Mr. SH Kim, Procurement Manager at Samsung C&T Corporation, commented, “In Hitachi Energy, we have selected a trusted partner who brings deep global competence and a strong mindset of collaboration and innovation.” SH Kim continued, “Together, we will serve ADNOC with pioneering technologies that are proven to deliver for such a large HVDC project.”
The entire power-from-shore project will comprise two HVDC power links, which will connect two clusters of offshore oil and gas production facilities to the mainland power grid, a distance of up to 140 kilometers for each cluster.
Hitachi Energy is supplying four converter stations, which convert AC power to DC for transmission in the subsea cables, then reconvert it to AC from DC for use in the offshore power systems. The HVDC technology will be supplied from Hitachi Energy’s global competence centers. Also included in the order are system studies, design and engineering, supply, installation supervision and commissioning. Hitachi Energy will support the customers with a long-term life-cycle service agreement leveraging digital technologies to ensure system availability and reliability over the HVDC links’ long operating life.
HVDC Light is a voltage source converter technology that was pioneered by Hitachi Energy. It is the preferred technology for many grid applications, including interconnecting national power grids, integrating offshore wind parks with mainland transmission systems, feeding more power into congested city centers, interconnecting asynchronous networks that operate at different frequencies, and power from shore.
HVDC Light’s defining features include uniquely compact converter stations (which is extremely important in space-critical applications like offshore wind, offshore production facilities and city-center infeeds), exceptionally low electrical losses, and black-start capability to restore power after a grid outage.
Hitachi Energy pioneered commercial HVDC technology almost 70 years ago and has delivered more than half of the world’s HVDC Classic projects and more than 70 percent of the world’s voltage source conversion HVDC projects.
The estimated reduction in carbon footprint is based on Hitachi Energy’s own calculations.
About Hitachi Energy
Hitachi Energy is a global technology leader that is advancing a sustainable energy future for all. We serve customers in the utility, industry and infrastructure sectors with innovative solutions and services across the value chain. Together with customers and partners, we pioneer technologies and enable the digital transformation required to accelerate the energy transition towards a carbon-neutral future. We are advancing the world’s energy system to become more sustainable, flexible and secure whilst balancing social, environmental and economic value. Hitachi Energy has a proven track record and unparalleled installed base in more than 140 countries. Headquartered in Switzerland, we employ around 38,000 people in 90 countries and generate business volumes of approximately $10 billion USD.
DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) — Data from the HIV Prevention Trials Network (HPTN) studies HPTN 083 and HPTN 084 helped provide important information for yesterday’s decision by the U.S. Food and Drug Administration (FDA) to approve ViiV Healthcare’s long-acting cabotegravir (CAB-LA) injections for the prevention of HIV. Sponsored and co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), these studies showed that CAB-LA injected once every eight weeks was superior to daily oral tenofovir/emtricitabine (TDF/FTC) for HIV prevention among cisgender men and transgender women who have sex with men (HPTN 083) and cisgender women (HPTN 084). Both studies also demonstrated that CAB-LA was well-tolerated, offering a new and important pre-exposure prophylaxis (PrEP) option for individuals at risk for HIV infection. ViiV Healthcare will market CAB-LA for PrEP under the brand name Apretude.
“This is a truly critical milestone for HIV pre-exposure prophylaxis providing a safe and effective alternative to daily pills,” said Dr. Myron Cohen, HPTN co-principal investigator, and director of the Institute for Global Health at the University of North Carolina in Chapel Hill. “Until we have a cure or vaccine, more prevention options that meet the needs of individuals at risk for HIV around the world are essential.”
HPTN 083 was co-funded by NIAID and ViiV Healthcare. HPTN 084 was co-funded by NIAID, the Bill & Melinda Gates Foundation, and ViiV Healthcare. Study product was provided by ViiV Healthcare and Gilead Sciences, Inc. Three other NIH institutes also collaborated on HPTN 083 and HPTN 084: the National Institute of Mental Health, the National Institute on Drug Abuse, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
HPTN 083 enrolled 4,570 cisgender men and transgender women who have sex with men at research sites in Argentina, Brazil, Peru, South Africa, Thailand, the U.S., and Vietnam. In the study, 52 HIV infections occurred, with 12 new infections in the CAB arm and 39 new infections in the TDF/FTC arm. These findings translate to a 69 percent reduction in incident HIV infections in study participants given CAB-LA compared to TDF/FTC.
HPTN 084 enrolled 3,223 cisgender women at research sites in Botswana, Eswatini, Kenya, Malawi, South Africa, Uganda, and Zimbabwe. There were three new infections in the CAB arm and 36 new infections in the TDF/FTC arm, a 92 percent reduction in incident HIV infections in study participants given CAB-LA compared to TDF/FTC.
“HIV continues to disproportionately impact specific populations who need new HIV prevention options that are not only convenient but also highly effective,” said Dr. Wafaa El-Sadr, HPTN co-principal investigator, director of ICAP, and professor of epidemiology and medicine at Columbia University in New York. “CAB-LA is a long-awaited and welcomed addition to the HIV prevention toolkit, offering a potentially convenient option for so many around the world.”
About the HPTN
The HIV Prevention Trials Network (HPTN) is a worldwide collaborative clinical trials network that brings together investigators, ethicists, community members, and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. The U.S. National Institute of Allergy and Infectious Diseases, the U.S. National Institute of Mental Health, Office of The Director, the U.S. National Institute on Drug Abuse, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, all part of the U.S. National Institutes of Health, co-fund the HPTN. The HPTN has collaborated with more than 85 clinical research sites in 19 countries to evaluate new HIV prevention interventions and strategies in populations with a disproportionate HIV burden. The HPTN research agenda – more than 50 trials ongoing or completed with over 161,000 participants enrolled and evaluated – is focused primarily on discovering new HIV prevention tools and evaluating integrated strategies, including biomedical interventions combined with behavioral risk reduction interventions and structural interventions. For more information, visit hptn.org.
Rancho Santa Margarita, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) — Blue California, the producer of natural science-based ingredients, provides FineCap™ a comprehensive microencapsulation technology platform, equipped with 20 microencapsulation technologies, to deliver active ingredients and satisfy our clients’ needs.
Microencapsulation is the process in which tiny particles of solid, liquid, or gas are packaged within a matrix to form a capsule. The capsule is coated with a protective layer to avoid degradation from exposure to environmental factors such as water, oxygen, heat, and light.
“Brands that seek to expand their products’ qualities and boost their product portfolios will find many benefits to the FineCap platform,” said Dr. Cuie Yan, vice president of encapsulation. “FineCap takes microencapsulation a step further by offering a variety of technologies and targeting customers’ specific needs in tackling active ingredients with unique characteristics, such as strong odor, taste or stability problems that challenge formulators.”
Microencapsulation systems have been widely used across multiple industries, including the pharmaceutical, food, supplement, personal care, and fragrance industries, for active ingredients like medicines, nicotine, flavors/fragrances, polyunsaturated fatty acids, probiotics, natural pigments, vitamins, antioxidants, etc. Space agency NASA also uses encapsulation technologies for spacecraft. The pharmaceutical industry uses microencapsulation often to control the release of active pharma ingredients (API).
Blue California has created the FineCap platform to serve customers’ growing demands for better performance of API, functional ingredients, dietary supplements, flavors, fragrances, cosmetics, and personal care products.
For example, FineCap protects API from degradation, unpleasant tastes or aroma, and maintains its efficacy, by controlling its release. FineCap enables flavors to thrive in food and beverages with integrity, intensity, and extended shelf-life.
In fragrances, FineCap guarantees brands to control the precise fragrance release rate, location, and duration. Personal care products benefit from FineCap by protecting the delicate top-notes and cosmetic actives from oxygen, moisture, temperature, and light deterioration. A more comprehensive look into the benefits that FineCap delivers in these product segments can be found here.
“Our comprehensive FineCap platform has been serving and supporting formulators looking to launch market-winning products with better qualities and shelf-life that consumers are seeking,” said Dr. Yan. “We’re enabling brands to quickly create products from innovative concepts, benchtop development, to pilot and full commercial manufacturing, with improved efficacy, taste, color, texture, and shelf life, along with vegan, organic, Kosher, or Halal certificate.”
The FineCap platform investment builds on Blue California’s 25-year legacy of producing botanical extracts and now natural flavors and fragrances and focuses on developing sustainable ingredients made through bioconversion or fermentation.
###
About Blue California
Blue California is an entrepreneurial, science-based solutions provider and manufacturer of clean, natural, and sustainable ingredients used in food, beverage, flavor, fragrance, dietary supplements, personal care, and cosmetic products. For more than 25 years, Blue California has built a strong reputation for creating value in these diverse natural products and nature-inspired industries.
MAPUTO, Mozambique, Dec. 21, 2021 /PRNewswire/ — Globeleq, the leading independent power company in Africa and its project partners, Source Energia, a Lusophone Africa energy developer and Electricidade de Moçambique (EDM), the Mozambican national power utility, have reached financial close on the 19MWp (15MWac) Cuamba Solar PV plant with a 2MW (7MWh) energy storage system.
The US$36 million project located in the Cuamba district, Niassa province (about 550 km west of the coastal town of Nacala) will supply electricity through a 25-year power purchase agreement with EDM. The project is the first IPP in Mozambique to integrate a utility scale energy storage system and includes an upgrade to the existing Cuamba substation.
Once operational, the Cuamba Solar plant will supply enough power for 21,800 consumers, and over the life of the project is expected to avoid the equivalent of more than 172,000 tonnes of CO2 emissions. First power is expected to flow in the second half of 2022.
The Emerging Africa Infrastructure Fund (“EAIF”), a member of the Private Infrastructure Development Group (“PIDG”) provided US$19 million in debt funding, with PIDG’s Viability Gap Funding (VGF) grant facility providing US$7million to enable an affordable tariff, fund essential grid upgrades and an energy storage system for EDM. CDC Plus, the technical assistance facility of CDC Group, has contributed a US$1million grant towards the battery energy storage system.
Olivia Carballo, a Director at Ninety One Ltd, the managers of EAIF, commented: “This is a pioneering project for EAIF and PIDG. We congratulate Globeleq, Source Energia, EDM and Mozambique on reaching a key milestone in deploying more solar technology to the northern grid, and on installing Mozambique’s first grid-scale battery energy storage system.”
Sarah Marchand, CDC Director, CDC Plus, said: “We are delighted to support one of sub-Saharan Africa’s first grid-scale battery energy storage systems through this grant for the battery storage system. In line with CDC’s ambition to catalyse more storage solutions across the continent, CDC Plus will also offer support to capture and disseminate learnings around the battery component’s operational, economic, and development impact.”
“With the ongoing challenges due to the pandemic, I am proud our team has achieved financial close, and we can begin building the first solar and energy storage facility in the country. We fully support the Mozambican Government in their initiatives to support the Paris Agreement and provide its citizens with reliable and clean alternative energy options,” added Mike Scholey, Globeleq’s CEO.
EDM’s Chairman, Marcelino Gildo Alberto said: “This project is a demonstration of EDM’s commitment to provide sustainable solutions to speed up energy access to Mozambicans. In compliance with the Government’s Five-Year Plan to introduce 200MW of renewable energy, EDM is at the forefront of the energy transition in line with the Paris Agreement.”
“We are very pleased to make another contribution to the Mozambique Energy sector and look forward to supporting the future growth of the industry in the country. Our thanks go to our project partners and funders for their unparalleled patience and commitment during the development phase,” said Pedro Coutinho, CEO of Source Energia
The project will require approximately 100 workers during construction, many of whom will be hired from the local community. The Spanish company Grupo TSK has been appointed as the project EPC contractor and will immediately commence mobilisation of its construction team. E22, part of the Spanish Gransolar Group, will supply the complete battery energy storage system. Globeleq will oversee the construction and operations of the power plant, supported by Source Energia.
